ABT-263 administration in ex vivo normothermic kidney perfusion
Research type
Research Study
Full title
An Initial evaluation of ex vivo senescent cell depletion as an intervention to improve the long-term function of kidney transplants
IRAS ID
257452
Contact name
David A Ferenbach
Contact email
Sponsor organisation
University of Edinburgh
Clinicaltrials.gov Identifier
N/a, N/a
Duration of Study in the UK
2 years, 5 months, 31 days
Research summary
As we age, everyone accumulates more and more senescent cells (cells which no longer replicate, as a response to aging and stress) in many of our organs, including the kidneys. Recent work has shown that in mice, these non-replicating cells actively promote physical aging and frailty – and we believe that the same is likely to be true in man. Studies in man have already shown that senescent cells accumulate in kidney diseases, and that a kidney which has more senescent cells when transplanted is less likely to work in the longer term than one that has fewer senescent cells.\n\nThe aim of this study is to test a drug (‘ABT-263’) which we have shown in laboratory studies is capable of killing senescent cells, and protecting kidneys from progressive injury. ABT-263 is already being used in humans in other clinical studies. We plan to test this on human kidneys which have been deemed unsuitable for transplant, and determine whether this drug is a) safe, and b) effective in reducing the number of senescent cells present. If our results show that we can reduce the number of senescent cells safely, it should be possible to move quickly to a clinical study, aiming to improve the function and survival of human kidney transplants.\n
REC name
North of Scotland Research Ethics Committee 1
REC reference
19/NS/0113
Date of REC Opinion
27 Jun 2019
REC opinion
Favourable Opinion